“When I first joined Medtronic, it was shortly after the Covidien merger and we had taken on a lot of debt to do that transaction,” she said in an interview with Medical Design & Outsourcing.
When Medtronic (NYSE:MDT) CFO and EVP Karen Parkhill looks back at the medical device manufacturer’s performance through the COVID-19 pandemic, she recalls a key decision that rankled investors but paid off in the long run.